Martin Preyer
Executive Director - Biotherapeutics EvolveImmune Therapeutics
Martin Preyer is currently the Executive Director, Biotherapeutics at Evolveimmune Therapeutics, where he is leading the biologics drug discovery and protein engineering team. Prior to joining Evolveimmune, he has developed various biologics modalities including protease-activatable T cell engagers for cancer immunotherapy and other multispecifics. Martin received his PhD from the University of Natural Resources and Life Sciences in Vienna, Austria, and completed his postdoctoral training in the Laboratory of Genetics at the Salk Institute in La Jolla, CA.
Seminars
Join this workshop to master the structural complexity of next generation multispecifics, where the focus shifts from simple binding to the precise spatial coordination of the immunological synapse.
- Designing trispecifics that require two tumor antigens to trigger engagement, widening the therapeutic window
- Engineering trispecifics that require two different tumor antigens to trigger CD3 engagement, significantly widening the therapeutic index for antigens
- Overcoming engineering hurdles to ensure the two components of the TCE only meet on the tumor cell surface
- Technical deep-dive into target identification using TCR-target discovery engines to reduce minimal off-target reactivity
- Identifying the optimal inter-membrane distance and how the choice of epitopes on the tumor antigen dictates efficacy
- T‑cell engagers have shown positive clinical outcomes across multiple indications, including solid tumors, but currently approved molecules do not provide a direct co‑stimulatory signal
- The EVOLVE platform integrates CD2 co‑stimulation into CD3 multispecifics to enhance T‑cell activation, durability, and functional fitness
- An overview of the EVOLVE multispecific platform and highlight key design features that enable improved T‑cell engagement
